Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 4/20 | 0.31 |
| ▸ | DRD2 | P14416 | 4/20 | 0.31 |
| ▸ | DRD4 | P21917 | 4/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139278 | 0.81 | EPHX1 (0.38) | ALDH1A1 | |
| SCHEMBL2142404 | 0.81 | CTSD (0.40) | NAMPTCTSD | |
| SCHEMBL2141436 | 0.80 | EPHX2 (0.41) | ALDH1A1CTSD | |
| SCHEMBL3634426 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3634527 | 0.79 | EPHX2 (0.34) | PIK3CDCTSD | |
| SCHEMBL2142635 | 0.78 | PRMT3 (0.35) | NAMPTCTSD | |
| SCHEMBL2139793 | 0.78 | EPHX2 (0.35) | KMT2ANAMPTCTSD | |
| SCHEMBL2140176 | 0.75 | HTT (0.50) | KMT2ASMN1; SMN2 | |
| SCHEMBL2139218 | 0.73 | TDP1 (0.36) | NAMPTCTSD | |
| SCHEMBL3706915 | 0.72 | ECE1 (0.34) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | claimed |
| EP-2131854-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | Aeterna Zentaris Gmbh (DE) | 2009-12-16 | — | — | EP | claimed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | claimed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | claimed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | claimed |
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8148546-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2131854-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | Aeterna Zentaris Gmbh (DE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | KMT2A 4477/4885SMN1; SMN2 4297/4885TRPA1 291/4885 |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | LHCGR, GNRHR, FSHR | KMT2A 1560/4885SMN1; SMN2 3061/4885TRPA1 2409/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | KMT2A 4477/4885SMN1; SMN2 4297/4885TRPA1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.